Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary

Fri, 14 Jun 2024 10:58:11 +0000
Press Releases

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Expansion
Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary
14.06.2024 / 12:58 CET/CEST
The issuer is solely responsible for the content of this announcement.*Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary*

June 11, 2024, Lukácsháza, Hungary

· After EUR 76 million (HUF 28,044 billion) investment and 1.5 years of construction, SCHOTT Pharma opens its newest production facility in Lukácsháza, Hungary
· Expanding production capacity will support pharma megatrends and market growth for prefillable syringes made of specialty glass
· With financial support from the local government, the facility brings over 120 new jobs to the area

*After breaking ground in October 2022 and fresh of its IPO in September 2023, SCHOTT Pharma opened the doors to an entirely new production facility for high-quality prefillable glass syringes in Hungary. Supported by a EUR 9 million (HUF 3,321 billion) investment from the local government, SCHOTT Pharma’s double-digit million Euro investment is realized today with the opening of a facility that creates over 120 jobs. With this move, SCHOTT Pharma is expanding its global capacities for strategically important high-value solutions that address key pharma trends. At the same time, the company is strengthening its competitiveness in Europe and the supply security for major pharmaceutical companies and contract manufacturing organizations. To supply the fast and dynamically growing market, SCHOTT Pharma plans to further invest a multi-million Euro amount in Hungary in prefillable syringes in the next years.*

“With an increasing number of drugs being stored in prefillable glass syringes – from GLP-1 drugs to critical vaccines and innovative biologics, the manufacturing beginning at this site today will continue to support major trends in the pharma industry,” says Andreas Reisse, CEO of SCHOTT Pharma.

As evidenced by their growing demand in the healthcare industry, these high-quality prefillable glass syringes not only offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and clinicians.

Drug containment and delivery play a critical role in medication protocols. Traditionally, a newly developed drug is launched in vials, with healthcare providers using disposable syringes for extraction and administration. Today, more and more pharmaceutical companies are moving towards filling medicines directly into prefillable syringes to enable storage and administration in one, streamlining the injection process for healthcare professionals and improving the accuracy of dosing for patients.

SCHOTT Pharma’s Hungarian site, that was inaugurated in Lukácsháza today, builds on the company’s existing foundation and pharmaceutical production skillset in the area, which already plays an important role in supplying the global industry with drug containment systems today. Following the high-end processes and advanced quality assurance found in SCHOTT Pharma’s global production network in 14 countries, the facility is equipped with state-of-the-art machinery. The new site is the second site where the company manufactures glass syringes, in addition to the site in St. Gallen in Switzerland.More information on prefillable glass syringes: https://www.schott-pharma.com/en/products/syringes/syriq

*About SCHOTT Pharma*

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023.

*Press contact:*

Lea Kaiser
Communications Manager
+49 (0)6131/66-4073
Lea.Kaiser@schott.com

Jasko Terzic, CFA
Senior Manager Investor Relations
IR.Pharma@schott.com
--------------------

14.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com --------------------

Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany
ISIN: DE000A3ENQ51
WKN: A3ENQ5
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
EQS News ID: 1925735

End of News EQS News Service